Herceptin
Peyrot, J.
Oncology Nursing Forum 26(3): 515-516
1999
ISSN/ISBN: 0190-535X PMID: 10214591 Document Number: 501583
Document emailed within 1 workday
Related Documents
Kuhne, W. 2003: Site transfer and process validation in case of Herceptin APi Developments in Biologicals 113: 47-502012: Subcutaneous trastuzumab (Herceptin) injection shows promise Oncology 26(9): 873
Sliwkowski, M.X.; Lofgren, J.A.; Lewis, G.D.; Hotaling, T.E.; Fendly, B.M.; Fox, J.A. 1999: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Seminars in Oncology 26(4 Suppl. 12): 60-70
Burgess, E.P. 2006: Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article New Zealand Medical Journal 119(1237): U2065; Author Reply U2065
Fleming, T.R. 1999: Issues in the design of clinical trials: insights from the trastuzumab (Herceptin) experience Seminars in Oncology 26(4 Suppl. 12): 102-107
Tajima, T.; Suzuki, Y.; Tokuda, Y. 2002: Herceptin and its therapeutic strategy in patients with breast cancer overexpressing HER2 Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(7): 1132-1137
Kubo, M.; Morisaki, T.; Kuroki, H.; Tasaki, A.; Yamanaka, N.; Matsumoto, K.; Nakamura, K.; Onishi, H.; Baba, E.; Katano, M. 2003: Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer Anticancer Research 23(6a): 4443-4449
Sudo, T.; Aruga, A.; Shimizu, K.; Matsushita, N.; Takasaki, K. 2006: OK432-activated natural killer cells enhanced trastuzumab (Herceptin)-mediated antibody-dependent cellular cytotoxicity in patients with advanced cancer Anticancer Research 26(6b): 4327-4333
2015: Subcutaneous trastuzumab (Herceptin). Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab Prescrire International 24(159): 93